Phosphodiesterase-4B (PDE4B) Inhibitors for Alzheimer's Disease

Under the parent grantTetra Discovery Partners is developing phosphodiesteraseBPDE Ballosteric inhibitors as a treatment for major depressive disorderUniquelythe Tetra drug will address inflammation as a contributor to depressionThis is a new mechanism of action for an antidepressant drug which should prove complimentary to current therapeuticsThe company estimates thatof patients with depression have co morbid inflammation and will be ideal candidates for the Tetra drugAddressing inflammation will target currently untreatable patientssuch as those receiving interferonIFNfor viral illnessdepressed patients with co morbid psoriasisinflammatory bowel diseasetraumatic brain injuryor post traumatic stress disorderGiven the limitations of current treatmentsthere is a need for new medications with novel mechanisms of actionThe supplemental fund request will allow the company to assess the benefit of lead PDE B allosteric inhibitors in preclinical mouse models of Alzheimer s disease The prevalence of major depression is staggering with aroundof people experiencing depression at some point in their livesThusthere is a need for new medications with novel mechanisms of actionThe company proposes to develop phosphodiesteraseBPDE Binhibitors with a unique antidepressant anti inflammatory profile for treating depressionThe supplemental funding request will allow assessment of lead compounds in preclinical mouse models of Alzheimerandapos s disease